Burning Rock Biotech Ltd (BNR)

$3.75

+0.04

(+1.08%)▲

Market is closed - opens 7 PM, 08 Oct 2024

Performance

  • $3.61
    $4.27
    $3.75
    downward going graph

    3.73%

    Downside

    Day's Volatility :15.46%

    Upside

    12.18%

    downward going graph
  • $2.62
    $11.70
    $3.75
    downward going graph

    30.13%

    Downside

    52 Weeks Volatility :77.61%

    Upside

    67.95%

    downward going graph

Returns

PeriodBurning Rock Biotech LtdSector (Health Care)Index (Russel 2000)
3 Months
-38.38%
5.0%
0.0%
6 Months
-47.83%
5.9%
0.0%
1 Year
-61.95%
16.6%
0.0%
3 Years
-97.76%
18.9%
-21.4%

Highlights

Market Capitalization
38.1M
Book Value
$66.07
Earnings Per Share (EPS)
-7.86
Wall Street Target Price
4.03
Profit Margin
-111.18%
Operating Margin TTM
-82.06%
Return On Assets TTM
-30.91%
Return On Equity TTM
-68.89%
Revenue TTM
509.8M
Revenue Per Share TTM
49.75
Quarterly Revenue Growth YOY
-7.3%
Gross Profit TTM
380.0M
EBITDA
-445.4M
Diluted Eps TTM
-7.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Burning Rock Biotech Ltd(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 7.47%

Current $3.75
Target $4.03

Company Financials

FY18Y/Y Change
Revenue
30.3M
↑ 87.89%
Net Income
-25.8M
↑ 35.21%
Net Profit Margin
-84.98%
↑ 33.11%
FY19Y/Y Change
Revenue
54.4M
↑ 82.74%
Net Income
-24.0M
↓ 5.16%
Net Profit Margin
-44.1%
↑ 40.88%
FY20Y/Y Change
Revenue
65.7M
↑ 12.64%
Net Income
-57.1M
↑ 122.0%
Net Profit Margin
-86.93%
↓ 42.83%
FY21Y/Y Change
Revenue
79.7M
↑ 18.13%
Net Income
-125.1M
↑ 113.19%
Net Profit Margin
-156.87%
↓ 69.94%
FY22Y/Y Change
Revenue
80.7M
↑ 10.9%
Net Income
-139.2M
↑ 21.91%
Net Profit Margin
-172.44%
↓ 15.57%
FY23Y/Y Change
Revenue
75.3M
↓ 4.58%
Net Income
-91.5M
↓ 32.69%
Net Profit Margin
-121.63%
↑ 50.81%
Q1 FY23Q/Q Change
Revenue
20.6M
↓ 0.2%
Net Income
-31.4M
↑ 16.72%
Net Profit Margin
-152.02%
↓ 22.03%
Q2 FY23Q/Q Change
Revenue
17.8M
↓ 10.31%
Net Income
-24.4M
↓ 19.07%
Net Profit Margin
-137.17%
↑ 14.85%
Q3 FY23Q/Q Change
Revenue
16.6M
↓ 5.08%
Net Income
-22.2M
↓ 7.3%
Net Profit Margin
-133.97%
↑ 3.2%
Q4 FY23Q/Q Change
Revenue
17.6M
↑ 3.75%
Net Income
-17.0M
↓ 25.07%
Net Profit Margin
-96.76%
↑ 37.21%
Q1 FY24Q/Q Change
Revenue
18.8M
↑ 7.89%
Net Income
-15.0M
↓ 11.12%
Net Profit Margin
-79.71%
↑ 17.05%
Q2 FY24Q/Q Change
Revenue
18.7M
↑ 0.0%
Net Income
-14.9M
↑ 0.0%
Net Profit Margin
-79.71%
↑ 0.0%
FY18Y/Y Change
Total Assets
54.1M
-
Total Liabilities
141.7M
-
FY19Y/Y Change
Total Assets
120.8M
↑ 127.43%
Total Liabilities
247.9M
↑ 78.16%
FY20Y/Y Change
Total Assets
407.1M
↑ 214.2%
Total Liabilities
37.0M
↓ 86.08%
FY21Y/Y Change
Total Assets
357.8M
↓ 14.44%
Total Liabilities
68.0M
↑ 79.02%
FY22Y/Y Change
Total Assets
227.5M
↓ 30.33%
Total Liabilities
61.5M
↓ 0.96%
FY23Y/Y Change
Total Assets
145.6M
↓ 34.49%
Total Liabilities
38.0M
↓ 36.71%
Q1 FY23Q/Q Change
Total Assets
230.3M
↑ 12.0%
Total Liabilities
62.3M
↑ 15.42%
Q2 FY23Q/Q Change
Total Assets
162.9M
↓ 26.5%
Total Liabilities
42.4M
↓ 29.22%
Q3 FY23Q/Q Change
Total Assets
142.5M
↓ 10.86%
Total Liabilities
37.2M
↓ 10.59%
Q4 FY23Q/Q Change
Total Assets
137.9M
↓ 5.3%
Total Liabilities
37.5M
↓ 1.29%
Q1 FY24Q/Q Change
Total Assets
142.1M
↑ 3.9%
Total Liabilities
48.0M
↑ 28.89%
Q2 FY24Q/Q Change
Total Assets
141.1M
↑ 0.0%
Total Liabilities
47.6M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-21.6M
↑ 11.28%
Investing Cash Flow
15.4M
↓ 155.52%
Financing Cash Flow
12.1M
↓ 76.45%
FY19Y/Y Change
Operating Cash Flow
-32.5M
↑ 53.27%
Investing Cash Flow
-49.4M
↓ 426.76%
Financing Cash Flow
81.5M
↑ 585.59%
FY20Y/Y Change
Operating Cash Flow
-11.2M
↓ 67.75%
Investing Cash Flow
-16.7M
↓ 68.47%
Financing Cash Flow
331.1M
↑ 278.8%
FY21Y/Y Change
Operating Cash Flow
-75.0M
↑ 549.8%
Investing Cash Flow
12.8M
↓ 174.74%
Financing Cash Flow
-8.3M
↓ 102.44%
FY22Y/Y Change
Operating Cash Flow
-65.5M
↓ 4.41%
Investing Cash Flow
-1.1M
↓ 109.13%
Financing Cash Flow
-12.4M
↑ 63.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.8M
↓ 40.16%
Investing Cash Flow
-588.8K
↓ 19.35%
Financing Cash Flow
-1.5M
↑ 31381.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.6M
↓ 29.97%
Investing Cash Flow
-408.8K
↓ 27.86%
Financing Cash Flow
-6.4M
↑ 355.51%

Technicals Summary

Sell

Neutral

Buy

Burning Rock Biotech Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Burning Rock Biotech Ltd
Burning Rock Biotech Ltd
-22.71%
-47.83%
-61.95%
-97.76%
-98.49%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-0.56%
-7.19%
8.01%
-23.33%
75.58%
Agilent Technologies Inc.
Agilent Technologies Inc.
4.98%
0.35%
30.27%
-6.66%
93.04%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-3.52%
3.42%
20.66%
2.59%
107.02%
Danaher Corp.
Danaher Corp.
-1.12%
10.55%
23.66%
-10.77%
93.32%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-4.58%
-4.83%
15.18%
-5.73%
54.57%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Burning Rock Biotech Ltd
Burning Rock Biotech Ltd
NA
NA
NA
0.0
-0.69
-0.31
NA
66.07
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.39
47.39
5.03
10.59
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
30.14
30.14
3.13
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.18
37.18
2.23
21.73
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
49.73
49.73
2.67
7.59
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.57
29.57
1.15
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Burning Rock Biotech Ltd
Burning Rock Biotech Ltd
Buy
$38.1M
-98.49%
NA
-111.18%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.3B
75.58%
47.39
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.7B
93.04%
30.14
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$228.7B
107.02%
37.18
14.69%
Danaher Corp.
Danaher Corp.
Buy
$195.0B
93.32%
49.73
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.5B
54.57%
29.57
9.39%

Insights on Burning Rock Biotech Ltd

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 121.08M → 135.53M (in $), with an average increase of 3.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -216.22M → -108.03M (in $), with an average increase of 15.5% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 31.0% return, outperforming this stock by 92.3%

  • Vs TMO

    In the last 3 years, Burning Rock Biotech Ltd has experienced a drawdown of -97.8%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 91.1%

Institutional Holdings

  • Kynam Capital Management, LP

    9.50%

  • Massachusetts Financial Services Company

    3.81%

  • Fidelity International Ltd

    2.74%

  • Millennium Management LLC

    1.68%

  • Sumitomo Mitsui Trust Holdings Inc

    0.55%

  • Nikko Asset Management Americas Inc

    0.55%

Company Information

Headquartered in China and founded in 2014, Burning Rock, whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.

Organization
Burning Rock Biotech Ltd
Employees
786
CEO
Mr. Yusheng Han
Industry
Health Services

Discover More

FAQs